Study of the Genetic Variants in BRCA1/2 and Non-BRCA Genes in a Population-Based Cohort of 2155 Breast/Ovary Cancer Patients, Including 443 Triple-Negative Breast Cancer Patients, in Argentina

Angela R. Solano 1,2,*, Pablo G. Mele 2,3,*, Fernanda S. Jalil 1, Natalia C. Liria 1, Ernesto J. Podesta 2,3 and Leandro G. Gutiérrez 3

Abstract: Gene/s sequencing in hereditary breast/ovary cancer (HBOC) in routine diagnosis is challenged by the analysis of panels. The aim of this report is to describe a retrospective analysis of BRCA1/2 and non-BRCA gene sequencing in patients with breast/ovary cancer (BOC), including triple-negative breast cancer (TNBC). TNBC is associated to BRCA1/2 at a higher rate than the rest of the breast cancer types. The more prevalent pathogenic variants (PVs) in BRCA1/2 genes do not rule out the importance to panels of genes, although they are certainly far from shedding light on the gap of the 85% predicted linkage association of BOC with BRCA1/2 and are still not elucidated. This data is also of value in health programming for alerting risks in breast screening and knowledge of the regional spectrum of genetic variants.

Keywords: triple-negative breast cancer; NGS of gene panels; genetic predisposition to breast cancer; germline genetic testing

1. Introduction

Worldwide, breast cancer (BC) is the most common cancer in women, with diagnostics at a young age (pre-menopausal) being highly associated with hereditary factors...
increasing the risk of developing cancer [1]. Predisposition due to a germline variant has important implications for risk-reducing interventions, cancer screening, and germline testing for the affected patient and their close relatives [2,3] as well as for treatment decisions. Thus, germline genetic testing has become an integral part of the care of patients with BC and their families since \textit{BRCA1} (OMIM #113705) and \textit{BRCA2} (OMIM #600185) were identified in 1994 and 1995, respectively [4,5]. In fact, about 5% of all breast cancers bear a \textit{BRCA1/2} germline pathogenic variant (PV) [6], being a tissue sensitive to PARP inhibitors [7], and thus treatment with this type of molecule is feasible.

In the case of BC, there are different biological types that show considerable tissue-heterogeneity and thus extensive research has taken place for subtyping breast cancer at the molecular and genetic level to determine the various clinical, pathological, and molecular factors for the selection of treatment modalities and to visualize the prognosis of the disease at the time of diagnostics [8,9].

Breast cancers are categorized into three main groups based on cellular markers: (i) positive for estrogen receptors (ERs) and/or progesterone receptors (PRs); (ii) positive for amplification of human epidermal growth factor receptor 2 (HER2) with or without ER and PR positivity; and (iii) triple-negative breast cancer (TNBC), defined by a lack of ER/PR expression and HER2 amplification [8,10,11]. Targeted therapy is well defined and available for categories (i) and (ii); however, due to the aggressiveness and variety of the TNBC biology, frequently, treatment needs to be tailored according to the patient [12–14].

TNBC accounts for 10–20% of invasive breast cancers [6] and the developing risk is highly associated with age, race, and genetics [15]. Particularly, it is most frequently associated with younger pre-menopausal women (<42 years old) [15,16].

The pathogenic variant is present in about 20 to 50% of cases with BC and strong family history; individuals with such inheritance have a 50–80% risk of developing breast cancer in their lifetime [17,18]. However, much light needs to be shed on the genetics behind the development of TNBC because of the high aggressiveness of this type of BC and the necessity to tailor the treatment according to the patient. Germline pathogenic variants in the \textit{BRCA1} and \textit{BRCA2} genes have been associated with TNBC, with 60–70% of carriers of pathogenic variants displaying a TNBC phenotype [19]. Additional studies have identified \textit{BRCA1/2} pathogenic variants in up to 29% of patients of Ashkenazi Jewish ethnicity presenting with TNBC [20], 20% of those with TNBC diagnosed at a young age and/or with a family history of breast cancer, and 8–14% of those with TNBC unselected for family history [21,22].

On the other hand, increased knowledge about the human genome and advances in genomic technology have made it possible to simultaneously examine genes in exome/gene panels. In fact, recent advances in next-generation sequencing (NGS) technology have enabled simultaneous sequencing of multiple-gene panels [23], expanding the association of many cancers with different genes, although the results up to now have not filled the expectations, with a pathogenic variant detected conferring a much higher risk of developing cancer than those in the general population [24]. In this actual paradigm, in which the use of extensive multi-gene panels has become the standard for the identification of new genes and LPVs/PVs associated with BC, guidelines for genetic testing and strategies for cancer surveillance and prevention have been developed and incorporated into oncologic practice [25].

In this paper, we first examine and describe the findings in a large single-center study in South America (2155 cases), comparing the frequency and type of variants found in the subgroup of TNBC patients. Additionally, it was observed that \textit{BRCA1/2} germline PVs might be associated with prolonged survival only if women were diagnosed with TNBC [26].

We also examine the incremental of the LPV/PV frequency in inherited susceptibility genes detected by a broad universal testing strategy of \textit{BRCA1/2} analysis, compared to the use of the multiple-panel gene NGS strategy. This final analysis aims to evaluate the improvement in the percentage of detection of LPV/PV, as well as evaluate the
cost-effectiveness that the massive use of multiple panels can have in countries, such as Argentina, where the conditions of economic inequality in the population are preponderant.

2. Materials and Methods

2.1. Study Subjects

In this study, we included 1900 individuals selected by familial (at least two relatives, one of 1st and one of 2nd degree) and/or personal history of BOC analyzed for BRCA1 and BRCA2 genes referred to the Laboratory of Genotyping at Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), a university hospital located in Buenos Aires, Argentina, between January 2016 and December 2020. The criteria for inclusion in the gene panel study, recruiting 255 cases, as to have BOC not clearly associated with BRCA1/2 genes and thus the study was expanded to other related genes, or individuals with a personal and/or family history with BOC and related tumors, as selected by the clinician.

The inclusion criteria for the selection of the actionable genes included in the multigene panel were based on the recommendations in the Clinical Practice Guidelines in Oncology of the National Comprehensive Cancer Network guidelines (NCCN Guidelines®)-Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic (Version 1.2020) [25].

2.2. Samples Preparation

Genomic DNA were extracted from blood samples with EDTA in the MagNA® Pure LC instrument with a total DNA isolation kit I (Roche Diagnostics Argentina, Buenos Aires, Argentina), following the manufacturer’s instructions.

2.3. BRCA1/2 Testing

Sequence analysis of complete BRCA1 and BRCA2 was performed by next-generation sequencing (NGS) and large rearrangements by Multiple Ligation-dependent Probe Amplification assay (MLPA–MRC Holland, Amsterdam, Netherlands). The promoter region was not sequenced in NGS, and was only assayed by MLPA, according to the manufacturer’s instructions.

The NGS sequencing platform used to process patient samples was Illumina® (San Diego, CA, USA). Assays were designed to ensure at least 200× total coverage/base and amplify the complete coding sequences of BRCA1 and BRCA2 genes, including 20 to 50 intronic adjacent bases to each exon. Sequences with low coverage were also analyzed by Sanger to guarantee the total coverage of genes. Sanger sequencing was also used for the confirmation of variants detected by NGS that have clinical relevance (Class 4: likely pathogenic; and class 5: pathogenic).

2.4. Multiple-Gene Panel Analysis

The samples were analyzed by complete exome sequencing (WES) with the Illumina® platform with similar technic specifications as before (see BRCA1/2 testing) and filtered for the following genes: ATM, BRCA1, BRCA2, BRI1, CDH1, CHEK2, CDKN2A, EPCAM, MUTYH, NF1, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, and TP53. The genes filtered and analyzed for each individual are according to the clinician order. As well as for BRCA1/2 testing, sequences with low coverage were also analyzed by Sanger to guarantee the total coverage of the sequence and if it was the case, we confirmed the variants detected with clinical relevance (class 4: likely pathogenic; and class 5: pathogenic).

2.5. Large Rearrangements of BRCA1/2

Large rearrangements were measured by MLPA using SALSA MLPA Probemix P002-BRCA1 and SALSA MLPA Probemix P045-BRCA2/CHEK2 (MRC-Holland, Amsterdam, Netherlands) according to the manufacturer’s recommendations.

We confirmed the positive results with SALSA MLPA Probemix P087 and SALSA MLPA Probemix P077 for BRCA1 and BRCA2, respectively.
2.6. Data Analysis

The variants were nominated following the HGVS nomenclature rules. The transcripts used included: ATM: NM_000051.3; BRCA1: NM_007294.3; BRCA2: NM_000059.3; BRIP1: NM_32043.3; CDH1: NM_004360.3; CHEK2: NM_007194.3; CDKN2A: NM_000077.4; EPCAM: NM_2354.3; MUTYH: NM_01128425.1; NF1: NM_000267.3; NBN: NM_002485.4; PALB2: NM_24675.3; PMS2: NM_000535.5; PTEN: NM_000314.6; RAD51C: NM_058216.3; RAD51D: NM_002878.3; STK11: NM_000455.4; and TP53: NM_000546.5.

For all NGS, BRCA1/2 or multi-panel full sequencing studies, BAM files were analyzed in Alamut Software®. Through this procedure, we checked the adequate vertical and horizontal coverage of each gene requested for analysis. The presence of all the variants reported by the annotation file was verified and we extended the control for the detection of additional variants that were missed for some reason: low coverage of the region, low allelic frequency, or simply not listed because of an informatic error. This step is especially important to ensure the correct coverage and annotation of the variants for the final report. As previously mentioned, the presence of the pathogenic variants (class 4 and class 5) was confirmed by Sanger sequencing, as well as the regions with a vertical coverage with less than 20 reads/base.

The interpretation and clinical classification of the genetic variants were carried out according to the recommendations of the American College of Medical Genetics and Genomics (ACMG) [27]. In this sense, a five-tier system was used for the variants: class 1 (benign), class 2 (likely benign), class 3 (variant with uncertain clinical significance, VUS), class 4 (likely pathogenic), and class 5 (pathogenic). We used the following reference databases for the clinical significance report: ClinVar [28], LOVD3.0 [29], and UMD [30], as of December 2020. In silico analysis was conducted for missense variants to predict the functional compatibility for amino acid changes with the software Align-GVGD [31], SIFT [32], and Mutations Taster [33].

2.7. Statistical Analysis

GraphPad Prism (GraphPad Software, Inc., Jolla, CA, USA) was used for statistical studies. Statistical significance was determined by ANOVA followed by the Tukey test.

3. Results

In total, 2155 patients were analyzed, with 1900 patients analyzed for BRCA1/2 genes and 255 patients studied for a panel of the following genes: ATM, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM, MUTYH, NF1, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, and TP53, as described in the materials and methods, including 2074 women, as summarized in Table 1.

| Probands                        | Number of Probands (% of Total) |
|---------------------------------|---------------------------------|
| Total analyzed                  | 2155                            |
| Women                           | 2074                            |
| BRCA1/2                         | 1900                            |
| Panel of genes                  | 255                             |
| Likely pathogenic and Pathogenic variants | 372 (17.2)                  |
| BRCA1                           | 207 (9.6)                       |
| BRCA2                           | 152 (7.0)                       |
| Non-BRCA                        | 13 (0.6)                        |

The 2155 patients comprised 443 women with TNBC, 30 of which were studied with the panel of genes, resulting in two of them having a non-BRCA PV, as shown in Table 2. The mean age of diagnosis for the gene-panel group was 42.4 ± 10.7 years, significantly different from the TNBC group: 32.7 ± 9.7. The panels analyzed included two healthy women and one man, none of whom were a carrier of the LPV/PV detected.
Table 2. Non-BRCA likely pathogenic/pathogenic variants in 255 women with a breast cancer diagnosis analyzed by a panel of genes.

| ID    | Age | Gene   | Exon/Intron | HGVS c.     | HGVS p.       |
|-------|-----|--------|-------------|-------------|--------------|
| AN620 | 55  | CDH1   | 10          | c.1528dup   | Ala510Glyfs*27 |
| AN621 | 57  | CDKN2A | 2           | c.1176T>C   | Val392Gly    |
| AN622 | 56  | CHEK2  | 2           | c.279G>A    | Trp93*       |
| AN609 | 29  | CHEK2  | 3           | c.349A>G    | Arg117Gly    |
| AN623 | 56  | CHEK2  | 3           | c.349A>G    | Arg117Gly    |
| AN624 | 56  | CHEK2  | 8i          | c.846+1G>C  |              |
| AN625 | 56  | CHEK2  | 11          | c.1169A>C   | Tyr390Ser    |
| AN626 | 50  | CHEK2  | 11          | c.1209_1233del | Tyr404Valfs*2 |
| AN627 | 43  | CHEK2  | 13          | c.1427C>T   | Thr476Met    |
| AN628 | 43  | MUTYH  | 12          | c.1105del   | Ala371Profs*23 |
| AN629 | 46  | NBN    | 6           | c.657_661del| Lys219Asnfs*16 |
| AN630 | 43  | RAD51D | 1           | c.1A>G      | Met1Val      |
| AN610 | 35  | TP53   | 7           | c.742C>T    | Arg248Trp    |

*These are likely pathogenic variants; the rest are all pathogenic variants.

At diagnosis, mean ± SD years (range): 48.1 ± 9.1 (29–57). Individuals AN609 and AN610 are a TNBC patients. The panel is composed by the following genes: ATM, BRCA1, BRCA2, BRIP1, CDKN2A, CDH1, CHEK2, EPCAM, MUTYH, NF1, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, and TP53.

The total LPV/PV of the 2155 samples sequenced was 98.13% for BRCA1/2 and the rest (1.87%) for non-BRCA1/2 variants.

In Table 2, the LPV/PV in non-BRCA genes are listed, showing that most of the variants are class 5 (PV) and only two are class 4 (LPV). Interestingly, PV c.1528dup in CDH1 is novel to our knowledge.

Table 3 summarizes the results in 443 TNBC patients in both PV in BRCA1/2 and non-BRCA genes, showing a clear preponderance for PV in BRCA1, less than half in BRCA2, and little presence in non-BRCA genes.

### Table 3. Likely pathogenic/pathogenic variants in BRCA1/2 and non-BRCA detected in triple-negative breast cancer cases.

| TNBC Patients | Number |
|---------------|--------|
| Total         | 443    |
| Likely pathogenic/Pathogenic | 107 (24.1%) |
| BRCA1/2       | 105 (23.7%) |
| PV in BRCA1 (66.7%) | 70    |
| PV in BRCA2 (32.4%) | 34    |
| PV in BRCA1 & 2 (0.9%) | 1     |
| Non-BRCA1/2   |        |
| LPV in CHEK2  | 1 (0.23%) |
| PV in TP53    | 1 (0.23%) |

The full list of variants detected in the TNBC patients is listed in Table 4. Two cases have special characteristics: (a) AN500 has two PVs, as follows: a large rearrangement in BRCA1 c.(-7_8232)(80+1_81-1)del and a spliceogenic PV in BRCA2 c.1909+1G>A. Her personal history begins with an ovary carcinoma at age of 42 years with retroperitoneal and lung metastasis, to follow at 46 years old with a TNBC; details regarding the family history are lacking, with only two relatives with cancer. Her father was diagnosed with colon cancer at 74 years old and her paternal grandmother died of uterus cancer at 80 years old; (b) AN519 is a 26-year-old woman, bearing three pathogenic variants coexisting in exon 5 of BRCA1, one of which is the recurrent variant of Spanish origin c.211del, p.(Arg71Glyfs*17) and the other two are c.187_188del, p.(Leu63Metfs*2), and c.191G>A, p.(Cys64Tyr) with a personal history of metachronic bilateral breast carcinoma, TN in right breast to follow at the age of 38 years with a ductal infiltrating carcinoma in the contralateral breast. The family history is very limited: paternal uncle has prostate cancer at 65 years and the paternal grandmother died of breast cancer at 87 years.
### Table 4. Likely pathogenic/pathogenic variants detected in TNBC patients (n = 107).

| ID     | Age | Gene | Exon/Intron | HGVS c. | HGVS p.          |
|--------|-----|------|-------------|---------|------------------|
| AN500  | 46  | BRCA1| 2_2i        | c.(?-232)_(80+1_81-1)del |                  |
| AN501  | 39  | BRCA1| 2           | c.68_69del | Glu23Valfs*17    |
| AN502  | 46  | BRCA1| 2           | c.68_69del | Glu23Valfs*17    |
| AN503  | 43  | BRCA1| 2           | c.68_69del | Glu23Valfs*17    |
| AN504  | 30  | BRCA1| 2           | c.68_69del | Glu23Valfs*17    |
| AN505  | 35  | BRCA1| 2           | c.68_69del | Glu23Valfs*17    |
| AN506  | 35  | BRCA1| 2           | c.68_69del | Glu23Valfs*17    |
| AN507  | 50  | BRCA1| 2           | c.68_69del | Glu23Valfs*17    |
| AN508  | 46  | BRCA1| 2           | c.68_69del | Glu23Valfs*17    |
| AN509  | 37  | BRCA1| 2           | c.68_69del | Glu23Valfs*17    |
| AN510  | 37  | BRCA1| 2           | c.68_69del | Glu23Valfs*17    |
| AN511  | 35  | BRCA1| 2           | c.68_69del | Glu23Valfs*17    |
| AN512  | 44  | BRCA1| 2           | c.68_69del | Glu23Valfs*17    |
| AN513  | 63  | BRCA1| 2i          | c.81-1G>A |                  |
| AN514  | 37  | BRCA1| 3i        | c.134+2T>C |                  |
| AN515  | 25  | BRCA1| 3i_24_      | c.(134+1_135-1)_(*1383_?)del |                  |
| AN516  | 31  | BRCA1| 5          | c.140G>T  | Cys47Phe         |
| AN517  | 31  | BRCA1| 5          | c.181T>G   | Cys61Gly         |
| AN518  | 54  | BRCA1| 5          | c.181T>G   | Cys61Gly         |
| AN519  | 26  | BRCA1| 5          | c.187_188del | Leu63Metfs*2 |
| AN520  | 46  | BRCA1| 5          | c.187_191delinsATA | Leu63Iles*2 |
| AN521  | 35  | BRCA1| 5          | c.190_191ins19 | Cys64*     |
| AN522  | 47  | BRCA1| 5          | c.190_191ins19 | Cys64*     |
| AN523  | 35  | BRCA1| 5          | c.190T>G   | Cys64Arg        |
| AN519  | 26  | BRCA1| 5          | c.191G>A   | Cys64Tyr        |
| AN525  | 50  | BRCA1| 5          | c.211A>G   | Arg71Gly        |
| AN526  | 50  | BRCA1| 5          | c.211A>G   | Arg71Gly        |
| AN527  | 40  | BRCA1| 5          | c.211A>G   | Arg71Gly        |
| AN525  | 50  | BRCA1| 5          | c.211A>G   | Arg71Gly        |
| AN528  | 46  | BRCA1| 5          | c.211A>G   | Arg71Gly        |
| AN529  | 51  | BRCA1| 5          | c.211A>G   | Arg71Gly        |
| AN530  | 48  | BRCA1| 5          | c.211A>G   | Arg71Gly        |
| AN531  | 32  | BRCA1| 5          | c.211A>G   | Arg71Gly        |
| AN519  | 26  | BRCA1| 5          | c.211del   | Arg71Ilefs*17   |
| AN533  | 33  | BRCA1| 5i        | c.213-11T>G | Glu143*   |
| AN534  | 25  | BRCA1| 7          | c.427G>T   | Ser157*         |
| AN535  | 48  | BRCA1| 8          | c.470_471del | Gly143*   |
| AN536  | 47  | BRCA1| 11         | c.1039_1040del | Glu143*   |
| AN537  | 26  | BRCA1| 11         | c.1067del   | Glu347Valfs*2 |
| AN538  | 47  | BRCA1| 11         | c.1504_1507del | Glu356Argfs*18 |
| AN539  | 58  | BRCA1| 11         | c.1687C>T   | Gly356Argfs*18 |
| AN540  | 36  | BRCA1| 11         | c.2296_2299del | Ser766*   |
| AN541  | 41  | BRCA1| 11         | c.3228_3229del | Gly1077Alafs*8 |
| AN542  | 48  | BRCA1| 11         | c.3331_3334del | Glu1103Asns*5 |
| AN543  | 48  | BRCA1| 11         | c.3627dup   | Glu1210Argfs*9 |
| AN546  | 35  | BRCA1| 11         | c.3858_3861del | Ser1286Argfs*20 |
| AN547  | 28  | BRCA1| 11         | c.4042G>T   | Gly1348*      |
| AN548  | 38  | BRCA1| 11         | c.4065_4068del | Asn1355Lysfs*10 |
| AN549  | 48  | BRCA1| 11         | c.4183C>T   | Gln1395*      |
| AN550  | 31  | BRCA1| 13         | c.4201C>T   | Gln1401*      |
| AN551  | 38  | BRCA1| 13         | c.4327C>T   | Arg1443*      |
| AN552  | 40  | BRCA1| 13i-14i    | c.(4357+1_4358-1)_(4484+1_4485-1)del |                  |
| AN553  | 41  | BRCA1| 14         | c.4392del   | Ile1465*      |
| AN554  | 18  | BRCA1| 14         | c.4484G>T   | Arg1495Met    |
| AN555  | 38  | BRCA1| 15i        | c.4675+2T>A | Glu1495Met    |
| AN556  | 40  | BRCA1| 15i-17i    | c.(4675+1_4676-1)_(5074+1_5075-1)del |                  |
| AN557  | 38  | BRCA1| 15i-17i    | c.(4675+1_4676-1)_(5074+1_5075-1)del |                  |
### Table 4. Cont.

| ID    | Age | Gene  | Exon/Intron | HGVS c.       | HGVS p.          |
|-------|-----|-------|-------------|---------------|-----------------|
| AN558 | 38  | BRCA1 | 16          | c.4736_4739del | Pro1579Leufs*21 |
| AN559 | 32  | BRCA1 | 16          | c.4964_4982del | Ser1655Tyrfs*16 |
| AN560 | 55  | BRCA1 | 16          | c.4964_4982del | Ser1655Tyrfs*16 |
| AN561 | 38  | BRCA1 | 16i         | c.4986+4A>C    |                 |
| AN562 | 30  | BRCA1 | 17          | c.5030_5033del | Thr1677Iles*2    |
| AN563 | 25  | BRCA1 | 17          | c.5030_5033del | Thr1677Iles*2    |
| AN564 | 51  | BRCA1 | 17          | c.5030_5033del | Thr1677Iles*2    |
| AN565 | 33  | BRCA1 | 18          | c.5095C>T     | Arg1699Trp      |
| AN566 | 31  | BRCA1 | 18          | c.5123>C>A    | Ala1708Glu      |
| AN567 | 36  | BRCA1 | 19i-20i     | c.(5193+1_5194-1), (5227+1_5278-1)del |                 |
| AN568 | 37  | BRCA1 | 20          | c.5266dup     | Gln1756Profs*74 |
| AN569 | 33  | BRCA1 | 20          | c.5266dup     | Gln1756Profs*74 |
| AN570 | 45  | BRCA1 | 20          | c.5266dup     | Gln1756Profs*74 |
| AN571 | 30  | BRCA1 | 21          | c.5282>T>C    | Phe1761Ser      |
| AN572 | 37  | BRCA1 | 23          | c.5431>C>T    | Gln1811*        |
| AN573 | 47  | BRCA1 | 23          | c.5445>G>A    | Trp1815*        |
| AN574 | 54  | BRCA1 | 23i-24i     | c.(5467+1_5468-1), (1383_?)del |                 |
| AN575 | 38  | BRCA2 | 2           | c.51_52del    | Arg18Leufs*12   |
| AN576 | 38  | BRCA2 | 2           | c.51_52del    | Arg18Leufs*12   |
| AN577 | 44  | BRCA2 | 3           | c.156_157ins(Alu) |             |
| AN578 | 61  | BRCA2 | 3           | c.214A>C      | Asn72His        |
| AN579 | 46  | BRCA2 | 6i          | c.516+3A>G    |                 |
| AN580 | 46  | BRCA2 | 10          | c.1337T>A     | Leu446*         |
| AN581 | 46  | BRCA2 | 10i         | c.1909+1G>A   |                 |
| AN582 | 45  | BRCA2 | 11          | c.2657del     | Asn886Metfs*9   |
| AN583 | 36  | BRCA2 | 11          | c.2808_2811del | Ala938Profs*21  |
| AN584 | 30  | BRCA2 | 11          | c.2808_2811del | Ala938Profs*21  |
| AN585 | 40  | BRCA2 | 11          | c.2808_2811del | Ala938Profs*21  |
| AN586 | 40  | BRCA2 | 11          | c.2808_2811del | Ala938Profs*21  |
| AN587 | 32  | BRCA2 | 11          | c.2830A>T     | Lys944*         |
| AN588 | 43  | BRCA2 | 11          | c.3744_3747del | Ser1248Argfs*10 |
| AN589 | 56  | BRCA2 | 11          | c.3847_3828del | Val1128Lysfs*2  |
| AN590 | 41  | BRCA2 | 11          | c.4277del     | Thr1426Asnfs*22 |
| AN591 | 38  | BRCA2 | 11          | c.4928>T>C    | Val1643Ala      |
| AN592 | 26  | BRCA2 | 11          | c.5351dup     | Asn1784Lysfs*3  |
| AN593 | 47  | BRCA2 | 11          | c.5682C>G     | Tyr1894*        |
| AN594 | 43  | BRCA2 | 11          | c.5946del     | Ser1982Argfs*22 |
| AN595 | 78  | BRCA2 | 11          | c.5946del     | Ser1982Argfs*22 |
| AN596 | 44  | BRCA2 | 11          | c.6024dup     | Gln2009Alafs*9  |
| AN597 | 41  | BRCA2 | 11          | c.6024dup     | Gln2009Alafs*9  |
| AN598 | 57  | BRCA2 | 11          | c.6024dup     | Gln2009Alafs*9  |
| AN599 | 33  | BRCA2 | 11          | c.6275_6276del | Leu2092Profs*7  |
| AN600 | 40  | BRCA2 | 11          | c.6405_6409del | Asn2135Lysfs*3  |
| AN601 | 28  | BRCA2 | 11          | c.6596del     | Thr2199Ilesfs*7 |
| AN602 | 41  | BRCA2 | 15          | c.7480>C>T    | Arg2494*        |
| AN603 | 42  | BRCA2 | 18          | c.7985>C>T    | Thr2662Met      |
| AN604 | 38  | BRCA2 | 19          | c.8351G>A     | Arg2784Gln      |
| AN605 | 38  | BRCA2 | 19i         | c.8487+1G>A   |                 |
| AN606 | 57  | BRCA2 | 22          | c.8942A>G     | Gln2981Gly      |
| AN607 | 33  | BRCA2 | 25          | c.9481A>T     | Lys3161*        |
| AN608 | 29  | CHEK2 | 3           | c.349>A>G     | Arg117Gly       |
| AN609 | 35  | TP53  | 7           | c.742C>T     | Arg248Trp       |

§ Two pathogenic variants in BRCA1 and BRCA2 coexisting in the same patient AN500. ¥ Three pathogenic variants in exon 3 of BRCA1 coexisting in the same patient AN519.
Regarding the patients with ovary cancer, they were in a vast part previously described [34], and no further relevant data needed to be incorporated.

It is interesting that the high rate of above 50% in LPV/PV detected in patients diagnosed with both cancers (breast and ovary, synchronic, or metachronic) is kept in those numbers since our results published in 2012 [35] with only 134 patients, maintained with 940 probands [36] and consolidated in this work with 2155 patients in which the patients with both cancers showed a detection rate of a PV in BRCA1/2 of 51.8%.

Regarding the male patients, as depicted in Table 5, with only one exception that was diagnosed with melanoma, the rest are healthy male carriers of PV in BRCA1/2.

Table 5. Men with pathogenic variants in BRCA1/2; n = 12; age, in years ± SD (range): 48.8 ± 14.9 (19–76).

| ID    | Age | Tumor     | Gene  | Exon/Intron | HGVS c.       | HGVS p.          |
|-------|-----|-----------|-------|-------------|---------------|------------------|
| MC134 | 43  | No        | BRCA1 | 2           | c.68_69del    | Glu23Valafs*17   |
| MC162 | 53  | No        | BRCA1 | 2           | c.68_69del    | Glu23Valafs*17   |
| MC166 | 43  | No        | BRCA1 | 2           | c.68_69del    | Glu23Valafs*17   |
| MC167 | 31  | No        | BRCA1 | 20          | c.5266dup     | Gln1756Profs*74   |
| MC186 | 44  | No        | BRCA2 | 2           | c.51_52del    | Arg18Leufs*12    |
| MC140 | 59  | No        | BRCA2 | 10          | c.1670T>G     | Leu557*          |
| MC181 | 56  | No        | BRCA2 | 11          | c.2808_2811del| Ala938Profs*21   |
| MC130 | 62  | Melanoma  | BRCA2 | 11          | c.5796_5797del| His1932Glnfs*12  |
| MC146 | 19  | No        | BRCA2 | 11          | c.5946del     | Ser1982Argfs*22  |
| MC127 | 43  | No        | BRCA2 | 11          | c.5946del     | Ser1982Argfs*22  |
| MC126 | 76  | No        | BRCA2 | 11          | c.5946del     | Ser1982Argfs*22  |
| MC171 | 56  | No        | BRCA2 | 17          | c.7857G>A     | Trp2619*         |

Table 6 shows a summary of the tumors diagnosed in men that did not have LPV/PV in the NGS sequence for the BRCA1/2 genes and the carriers of PV.

Table 6. Summary of the results in male patients.

| Male Patients                        | Number | Age, Years ± SD (Range) |
|--------------------------------------|--------|-------------------------|
| Total                                | 81     |                         |
| Without LPV/PV detected              | 44     | 54.6 ± 12.2 (29–78)     |
| With tumor                           | 13     | 55.2 ± 13.4 (29–72)     |
| BrCa                                 | 1      | 45/70                   |
| BrCa/Melanoma                        | 7      | 52.4 ± 9.2 (38–65)      |
| Pancreas Ca                          | 20     | 56.5 ± 9.7 (40–78)      |
| Prostate Ca                          | 2      | 40/38 and 57/20         |
| Prostate Ca/Melanoma                 | 1      | 67/69                   |
| Healthy (*)                          | 25     | 53.1 ± 10.6 (33–67)     |
| With PV detected                     | 12     |                         |
| Healthy carriers (**)                | 11     | 48.8 ± 14.3 (19–76)     |
| Melanoma                             | 1      | 62                      |

*5 out of the 25 patients were tested by the panel of genes as described in the materials and methods. **8 out of the 12 patients bear a mutation in the BRCA2 gene, the rest in BRCA1 (see Table 5).

In the 1900 BRCA1/2 sequences, there were 18 healthy women (Table S1) and 12 male carriers of PV (Table 5). Table S1 lists the 199 women with PV with the spectrum of diagnosis in number of cases as follows: breast cancer (no-TNBC), 40 and 45; ovary cancer, 41 and 36; breast and ovary cancer, 8 and 10; and no cancer, 12 and 6, in BRCA1 and BRCA2, respectively, and a single case of melanoma with the recurrent PV in BRCA2 c.2808_2811del, p.(Ala938Profs*21) in a 37-year-old proband.

In Table 7, the recurrent variants (detected three or more times) in non-related probands in BRCA1/2 among the total of 1900 patients are depicted. The three FVs of the Ashkenazi panel (c.68_68del and c.5266dup in BRCA1 and c.5946del in BRCA2) were not detected in non-Ashkenazi patients and are not included in the recurrent pathogenic variants.
Table 7. Recurrent pathogenic variants in BRCA1/2 detected in 1900 probands with personal and/or family history of breast/ovary cancer.

| Pathogenic Variant | Total Pathogenic Variants Detected = 359 | Unrelated Probands (% of the Total Probands) |
|--------------------|------------------------------------------|---------------------------------------------|
| BRCA1              |                                         |                                             |
| c.211A>G-p.(Arg71Gly)-¥ (7)                  | 13 (0.68)                                 |
| c.1360_1361del-p.(Ser454*)                  | 3 (0.16)                                  |
| c.4964_4982del-p.(Ser1655Tyrfs*16)-¥ (2)   | 4 (0.21)                                  |
| c.5030_5033del-p.(Thr1677Ilefs*2)-¥ (2)    | 4 (0.21)                                  |
| c.5123C>A-p.(Ala1708Glu)-¥ (1)             | 3 (0.16)                                  |
| BRCA2              |                                         |                                             |
| c.517G>T-p.(Gly173Cys)                      | 3 (0.16)                                  |
| c.1909+1G>A-¥ (1)                           | 4 (0.21)                                  |
| c.2808_2811del-p.(Ala938Profs*21)-¥ (4)    | 9 (0.47)                                  |
| c.5351dup-p.(Asn1784Lysfs*3)-¥ (1)         | 52 (2.74)                                 |
| Total recurrents = 9 PV                      |                                           |
| Total recurrents (52)/total PV (359) %      | 14.4%                                    |

Note: in a previous series, we describe two other recurrent pathogenic variants: c.181T>G-p.(Cys61Gly), detected in one proband in this cohort, and the c.6037A>T-p.(Lys2013*) never present in the 1900 probands [36]. ¥ These pathogenic variants (PVs) are present in TNBC; in parentheses, the number of cases bearing the PV.

Since the men we received as probands do not have a pathogenic variant and are healthy (with one exception with a melanoma, see Table 5), we considered this to be a good sample of what we have in Argentina for male carriers of PV. The relatives detected from the proband’s families discussed in this work, all of them healthy, are listed in the Table S2 (not included in the 2155 subjects of the cohort).

4. Discussion

The goal of this work was to update the spectrum of LPV/PV in BRCA1/2 and the first description of non-BRCA genes in Argentina associated with BOC, in particular in TNBC. The data is up to December 2020, based on 2155 new cases in women and men, with associated personal and/or family history, including the regional genetic variants launched in an early publication of ours [35]. In fact, in our actual reports of genetic variants, there are very few VUS present as a result of the more than 3000 fully sequenced patients deposited in the LOVD database, our platform for sharing data since 2016. In fact, we had many “VUS” highly frequent in our population and a high rate of them were coexistent with PV in BRCA1/2 [37]; thus, the high population frequency and the coexistence with PV lowered the classification to benign variants. As a sharing-data laboratory deposited at LOVD, we are listed at “ar.lovd.org” [38]. From our Country Node of the Human Variome Project, we encourage others to deposit the variants and, as a result, laboratories from many provinces in the country are depositing their genetic variants [39].

Besides, in one of our previous publications [36], we reported in the conclusions a high percentage of novel variants (pathogenic or not) in BRCA1/2. This is very contrasting data with the present work in which doubling of the number of cases with no novel variants in BRCA1/2 (only one novel variant in the CDH1 gene, c.1528dup). This is a result of the great amount of information in the last few years and the relevance of sharing data, which is key for the worldwide open genetic information to all scientists.

Table 1 shows a summary of the present study showing the BRCA1/2 and non-BRCA PV in the cohort, in 2074 women with 67.6% of the mutations in BRCA1, the most frequent mutated gene in most series [19].

In response to the demand from oncologists and genetic counselors for the analysis of panels of genes, 255 panels were analyzed for the genes composed by: ATM, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM, MUTYH, NF1, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, and TP53. The results in Table 2 show the LPV/PV detected with 13 LPV/PV, with only 2 LPV (c.1169A>C and c.1427C>T) and the rest were PV. The novel variant in CDH1, c.1528dup, is a frameshift resulting in an expected truncated
protein p.(Ala510Glyfs*27) in codon 537 and this is one codon reported as pathogenic (stop codon 536) at the LOVD data base (variant ID at LOVD: 00032560, 2004). This is finding supports the PV classification in concordance with the in silico analysis results.

A reiterate finding in the survival curve for TNBC exists, in which patients commonly show a sharp decrease in survival during the first 3 to 5 years after diagnosis. This type of breast cancer is biologically aggressive and many are potentially curable, reflecting their heterogeneity [40,41]. Thus, the eventual association with gene variants might be of great help in surveillance issues in at least two goals: screening for high-risk cases and treatment with specific drugs in the context of precision medicine for TNBC. For this reason, we focused on the TNBC patients in this cohort since it might help achieve both goals as well as identify regional variants in a zone of the world lacking large series analysis.

Most of the variants in TNBC (Table 3) have a PV in the BRCA1 gene (70 patients) with a median age in years of 39.5 ± 9.5 and a range of 18 to 63 years, compared to the BRCA2 PV with 34 probands with 42.5 ± 9.8 years (range 26–78); only one patient showed a PV in both genes. This is consistent with other publications reporting a greater rate of association with TNBC [19]. Only two non-BRCA gene variants were detected in this series of TNBC.

The Ashkenazi PV c.68_69del is present in 12 TNBC patients (vs. two patients in the non TNBC listed in Table S1). This is a strong association for this variant as a predictor of a high risk in women bearing this variant. A similar situation is observed the recurrent variant in BRCA1 c.211G>A, 7 times in TNBC.

Regarding the male patients, there are other publications concentrated on this matter describing tumors in men [42] that give an excellent description, concluding that “surveillance programs in men with BRCA1 and BRCA2 pathogenic variants should be tailored in light of these gene-specific cancer phenotype differences. These results may inform the design of prospective studies on cancer risks in male BRCA1 and BRCA2 pathogenic variant carriers”. As contributors in this publication, we take these conclusions since in the actual series, we did not recruit enough men to allow us to draw a summary, although it reinforces the silent manifestations in the men as carriers of PV in BRCA1/2. Table 6 shows that the age of diagnosis is beyond 50 years and the unique diagnosis, a melanoma, was at 62 years.

Table 7 shows the recurrent PV in BRCA1/2, in which 9 variants in total with a 2.74% coverage is a very low rate to be used for public health purposes, i.e., in a panel for lowering the cost for population screening. This confirms the lack of utility of the “Hispanic panel” [43] in our population as we already anticipated [36]. In conclusion, the recurrent mutations were not enough to anticipate a panel of PV to simplify the testing in the population unfortunately.

The Table S1 shows a list of 199 PV in non-TNBC detected in the 1900 patients analyzed and the age (range) in years for each cancer as follows: BRCA1: BrCa, 44.1 ± 8.8 (n = 41); OvCa: 52.9 ± 10.4 (n = 41); BOC, 45.9 ± 7.9 (n = 8) and No tumor: 38.8 ± 10.0 (n = 12) and for BRCA2: BrCa, 43.1 ± 10.8 (n = 44); OvCa: 56.8 ± 7.0 (n = 36); BOC, 45.5 ± 10.4 (n = 10) and No tumor: 50.5 ± 9.0 (n = 6). The ages showed no significant difference between both genes in BrCa and BOC, which is somewhat surprising, although there may be too few cases to be conclusive. The group with OvCa and with no tumor were significantly different (p < 0.001 and p < 0.01, respectively), with an older age for the BRCA2 gene, consistent with the reported data. The age at diagnosis for BrCa and OvCa in both genes showed significantly older probands for OvCa, consistently described in the majority of previous publications.

In most of the publications related to BRCA1/2 in the general population, there is a preponderance of women. For this reason, we thought it might be informative for the list of healthy men carriers of a pathogenic variant in BRCA1/2 with a wide range of age, 19–71, in Table S2. These men were not included in the cohort since all are relatives of the probands analyzed (only affected or healthy probands with a strong family history were included in the study). All the PV are highly penetrant; this is the reason men are considered “silent” carriers (not mute).
The best news is the precision medicine treatments associated with BRCA1/2 LPV/PV in TNBC preferably; detection ensured by good-quality DNA sequencing supporting the necessity of a high level in genetic reports as the basis of the best success for treatments. This data is also of value in surveillance programming for the highest risk in TNBC cases in breast cancer screening and the lessons from the regional spectrum of genetic variants in BRCA1/2 and expecting to be enlarged, or not, in the non-BRCA variants.

5. Conclusions

In conclusion, TNBC is associated with BRCA1/2 at a higher rate than the rest of the breast cancer types and targeted therapy treatment needs to be frequently tailored according to the patient. For these reasons, genetic testing is highly indicated. The most aggressive TNBC calls for stronger surveillance of carriers with higher probabilities of developing this type of cancer and, also, since the diagnosis is usually at younger age, the detection of carriers helps to prevent cancer in these persons. The more prevalent LPV/PV in BRCA1/2 genes (mostly in BRCA1) does not rule out the importance of panels of genes being tested.

Supplementary Materials: The following are available online: https://www.mdpi.com/article/10.3390/cancers13112711/s1, Table S1. Pathogenic variants detected in the women probands of the cohort, n = 181 for patients and n = 18 for healthy carriers (TNBC probands are in the main part). Table S2: Male individuals with pathogenic variant detected without cancer manifestation, relatives of the probands in the cohort and not included in the 2155 individuals.

Author Contributions: Conceptualization, A.R.S., L.G.G., E.J.P.; Data curation: F.S.J., L.G.G., P.G.M.; Formal analysis: A.R.S., L.G.G.; Methodology: F.S.J., L.G.G., N.C.L.; Project administration: A.R.S.; Writing-review and editing: A.R.S., L.G.G., P.G.M., E.J.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of CEMIC (IRB: IORG0001315, CEMIC, 2020).

Informed Consent Statement: Study eligibility after genetic counseling required signing an informed consent as a result of the routine procedures for genetic analysis (including Ethics Committee approval) at Centro de Educación Médica e Investigaciones Clínicas, which also complies with the Traditional Pretest Counseling for Susceptibility Testing (purpose of testing) described in the American Society of Clinical Oncology Policy Statement Update.

Data Availability Statement: The data presented in this studio are openly available in Leiden Open Variation Database, reference number [29].

Acknowledgments: Thanks to all the patients and their families for participating in this study. The following institutions make this publication possible: Departamento de Análisis Clínicos, DAM, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC); INBIOMED, Facultad de Medicina, UBA/CONICET; Pfizer Oncology and Node of Argentina of the Human Variome Project.

Conflicts of Interest: The authors declare no conflict of interests.

References
1. Samadder, N.J.; Giridhar, K.V.; Baffy, N.; Riegert-Johnson, D.; Couch, F.J. Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes. Mayo Clin. Proc. 2019, 94, 1084–1098. [CrossRef]
2. Rebbeck, T.R.; Friebel, T.M.; Friedman, E.; Hamann, U.; Huo, D.; Kwong, A.; Olah, E.; Olopade, O.I.; Solano, A.R.; Teo, S.H.; et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum. Mutat. 2018, 39, 593–620. [CrossRef]
3. Samadder, N.J.; Riegert-Johnson, D.; Boardman, L.; Rhodes, D.; Wick, M.; Okuno, S.; Kunze, K.L.; Golafshar, M.; Uson, P.L.S., Jr.; Mountjoy, L.; et al. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. JAMA Oncol. 2021, 7, 230–237. [CrossRef]
4. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.M.; Ding, W.; et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266, 66–71. [CrossRef]

5. Wooster, R.; Bignell, G.; Lancaster, J.; Swift, S.; Seal, S.; Mangion, J.; Collins, N.; Gregory, S.; Gumbs, C.; Micklem, G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378, 789–792. [CrossRef] [PubMed]

6. Foulkes, W.D.; Smith, I.E.; Reis-Filho, J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363, 1938–1948. [CrossRef]

7. Robson, M.; Im, S.A.; Senkus, E.; Xu, B.; Domchek, S.M.; Masuda, N.; Delaloge, S.; Li, W.; Tung, N.; Armstrong, A.; et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med. 2017, 377, 523–533. [CrossRef]

8. Kumar, P.; Aggarwal, R. An overview of triple-negative breast cancer. Arch. Gynecol. Obstet. 2016, 293, 247–269. [CrossRef] [PubMed]

9. Cancer Genome Atlas, N. Comprehensive portraits of human breast tumours. Nature 2012, 490, 61–70. [CrossRef] [PubMed]

10. Wolff, A.C.; Hammond, M.E.; Hicks, D.G.; Dowsett, M.; McShane, L.M.; Allison, K.H.; Allred, D.C.; Bartlett, J.M.; Bilous, M.; Fitzgibbons, P.; et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 2013, 31, 3997–4013. [CrossRef]

11. Silvestri, M.; Cristaudo, A.; Morrone, A.; Messina, C.; Bennardo, L.; Nistico, S.P.; Mariano, M.; Cameli, N. Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review. Drug Saf. 2021. [CrossRef]

12. Jhan, J.R.; Andrechek, E.R. Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics 2017, 18, 1595–1609. [CrossRef] [PubMed]

13. Severson, T.M.; Peeters, J.; Majewski, I.; Michaut, M.; Bosma, A.; Schouten, P.C.; Chin, S.F.; Pereira, B.; Goldgraben, M.A.; Bismeyer, T.; et al. BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Mol. Oncol. 2015, 9, 1528–1538. [CrossRef] [PubMed]

14. Yin, L.; Duan, J.J.; Bian, X.W.; Yu, S.C. Triple-negative breast cancer molecular subtype and treatment progress. Breast Cancer Res. 2020, 22, 61. [CrossRef] [PubMed]

15. Hahnen, E.; Lederer, B.; Hauke, J.; Loibl, S.; Krober, S.; Schneeweiss, A.; Denkert, C.; Fasching, P.A.;Blohmmer, J.U.; Jackisch, C.; et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol. 2017, 3, 1378–1385. [CrossRef] [PubMed]

16. Kwan, M.L.; Kushi, L.H.; Weltzien, E.; Maring, B.; Kutner, S.E.; Fulton, R.S.; Lee, M.M.; Ambrosone, C.B.; Caan, B.J. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009, 11, R31. [CrossRef] [PubMed]

17. Roy, R.; Chun, J.; Powell, S.N. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat. Rev. Cancer 2011, 12, 68–78. [CrossRef] [PubMed]

18. Robson, M.; Offit, K. Clinical practice. Management of an inherited predisposition to breast cancer. N. Engl. J. Med. 2007, 357, 154–162. [CrossRef] [PubMed]

19. Afghahi, A.; Telli, M.L.; Kurian, A.W. Genetics of triple-negative breast cancer: Implications for patient care. Curr. Probl. Cancer 2016, 40, 130–140. [CrossRef]

20. Comen, E.A.; Davids, M.; Kirchhoff, T.; Balistreri, L.; Hansen, J.; Kosarin, K.; Offit, K.; Robson, M.E. Prevalence of BRCA1 and BRCA2 mutations in Jewish women with triple negative breast cancer. J. Clin. Oncol. 2008, 26, 22002. [CrossRef]

21. Robertson, L.; Hanson, H.; Seal, S.; Warren-Perry, M.; Hughes, D.; Howell, I.; Turnbull, C.; Houlston, R.; Shanley, S.; Butler, S.; et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br. J. Cancer 2012, 106, 1234–1238. [CrossRef] [PubMed]

22. Andres, R.; Pajares, I.; Balmana, J.; Llor, G.; Ramon, Y.C.T.; Chirivella, I.; Aguirre, E.; Robles, L.; Lastra, E.; Perez-Segura, P.; et al. Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC). Clin. Transl. Oncol. 2014, 16, 280–284. [CrossRef] [PubMed]

23. Kurian, A.W.; Ford, J.M. Multigene Panel Testing in Oncology Practice: How Should We Respond? JAMA Oncol. 2015, 1, 277–278. [CrossRef]

24. Stadler, Z.K.; Thom, P.; Robson, M.E.; Weitzel, J.N.; Kauff, N.D.; Hurley, K.E.; Devlin, V.; Gold, B.; Klein, R.J.; Offit, K. Genomewide association studies of cancer. J. Clin. Oncol. 2010, 28, 4255–4267. [CrossRef] [PubMed]

25. National Comprehensive Cancer Network Guidelines. Available online: https://www.nccn.org/guidelines/category_1 (accessed on 28 December 2020).

26. De Talhouet, S.; Peron, J.; Vuilleumier, A.; Friedlaender, A.; Viassolo, V.; Ayme, A.; Bodmer, A.; Treilleux, I.; Lang, N.; Tille, J.C.; et al. Clinical outcome of breast cancer in BRCA1 carriers and BRCA2 mutations according to molecular subtypes. Sci. Rep. 2020, 10, 7073. [CrossRef]

27. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [CrossRef] [PubMed]

28. ClinVar. Available online: https://www.ncbi.nlm.nih.gov/clinvar/ (accessed on 28 December 2020).
29. Leiden Open Variation Database. Available online: https://www.lovd.nl (accessed on 28 December 2020).
30. The UMD Website. Available online: http://http://www.umd.be/ (accessed on 28 December 2020).
31. Align-GVGD. Available online: https://agvgd.iarc.fr/ (accessed on 28 December 2020).
32. Sorting Intolerant from Tolerant. Available online: http://sift.bii.a-star.edu.sg (accessed on 28 December 2020).
33. Mutation Taster. Available online: http://www.mutationtaster.org/ (accessed on 28 December 2020).
34. Cardoso, F.C.; Goncalves, S.; Mele, P.G.; Liria, N.C.; Sganga, L.; Diaz Perez, I.; Podesta, E.J.; Solano, A.R. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: Comparison with breast cancer variants in a similar population. Hum. Genom. 2018, 12, 39. [CrossRef] [PubMed]
35. Solano, A.R.; Aceto, G.M.; Delettieres, D.; Veschi, S.; Neuman, M.I.; Alonso, E.; Chialina, S.; Chacon, R.D.; Renato, M.C.; Podesta, E.J. BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. SpringerPlus 2012, 1, 20. [CrossRef]
36. Solano, A.R.; Cardoso, F.C.; Romano, V.; Perazzo, F.; Bas, C.; Recondo, G.; Santillan, F.B.; Gonzalez, E.; Abalo, E.; Viniegra, M.; et al. Spectrum of BRCA1/2 variants in 940 patients from Argentina including novel, deleterious and recurrent germline mutations: Impact on healthcare and clinical practice. Oncotarget 2017, 8, 60487–60495. [CrossRef]
37. Solano, A.R. Argentinian Node of the Human Variome Project. In Proceedings of the Personal Genomes (Virtual Conference), Wellcome Genome Campus, UK, 28 April 2021.
38. Leiden Open Variation Database (Chapter for Argentina). Available online: http://ar.lovd.org (accessed on 28 December 2020).
39. The Human Variome Project—Country Node of Argentina. Available online: https://humanvariomeprojectargentina.org.ar (accessed on 28 December 2020).
40. Tischkowitz, M.; Brunet, J.S.; Begin, L.R.; Huntsman, D.G.; Cheang, M.C.; Akslen, L.A.; Nielsen, T.O.; Foulkes, W.D. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007, 7, 134. [CrossRef]
41. Cheang, M.C.; Voduc, D.; Bajdik, C.; Leung, S.; McKinney, S.; Chia, S.K.; Perou, C.M.; Nielsen, T.O. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 2008, 14, 1368–1376. [CrossRef] [PubMed]
42. Silvestri, V.; Leslie, G.; Barnes, D.R.; Group, C.; Aagnarsson, B.A.; Aittomaki, K.; Alducci, E.; Andrulis, I.L.; Barkardottir, R.B.; Barroso, A.; et al. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol. 2020, 6, 1218–1230. [CrossRef] [PubMed]
43. Weitzel, J.N.; Clague, J.; Martir-Negron, A.; Ogaz, R.; Herzog, J.; Ricker, C.; Jungbluth, C.; Cina, C.; Duncan, P.; Unzeitig, G.; et al. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: A report from the Clinical Cancer Genetics Community Research Network. J. Clin. Oncol. 2013, 31, 210–216. [CrossRef] [PubMed]